ACE and essential hypertension: When scaled to represent SBP lowering achieved in clinical trials of ACE inhibitors for primary hypertension (equivalent to 8 mm Hg lower SBP), this represents an OR of 2.74 (95% CI 1.58 to 4.76) [69].